-+ 0.00%
-+ 0.00%
-+ 0.00%

Mérieux Equity Partners leads €31.5 million seed round for SRTD Biotech

PUBT·11/09/2026 07:02:41
Listen to the news
Mérieux Equity Partners leads €31.5 million seed round for SRTD Biotech
  • SRTD Biotech raised €31.5 million in an oversubscribed seed round led by Mérieux Equity Partners through its Mérieux Innovation 2 fund.
  • NRW.BANK and Boehringer Ingelheim Venture Fund co-led the financing.
  • Other participants included Lilly Ventures, HTGF and Anobis Asset.
  • The Jülich, Germany-based biotechnology company develops precision mRNA therapeutics designed to activate selectively within diseased cells.
  • Proceeds will fund preclinical development of targeted RNA therapies for oncology, autoimmune diseases and fibrosis toward investigational new drug applications.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merieux Equity Partners SAS published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.